State Key laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Department of Preventive Dentistry, West China Hospital of Stomatology, Sichuan University, No.14, 3Rd Section Of Ren Min Nan Rd., Chengdu, 610041, Sichuan, China.
BMC Oral Health. 2024 Sep 14;24(1):1086. doi: 10.1186/s12903-024-04846-x.
This single-blind randomized controlled trial was aimed to evaluate the microbiological and clinical effects of Zeger therapy on gingival health.
Twenty-four adults with gingivitis were recruited and monitored micro-biologically and clinically at baseline (Day 0), 4 weeks (Day 29) after therapy. All volunteers received one-stage full-mouth supragingival scaling as basic oral health care for baseline, and then randomly divided into experimental (koumiss, n = 12) or control (none, n = 12) group. The koumiss was used once a day for 4 weeks.
The microbial diversity of the experimental group increased significantly after drinking koumiss (p < 0.05), mainly owing to increasing of Gram-positive bacteria (p = 0.038) and oral health-related microbes (Rothia, Corynebacterium, Actinomyces, Saccharibacteria_TM7, etc.), decreasing of Gram-negative bacteria (p = 0.009) and periodontal disease-related microbes (Porphyromonas, Fusobacterium, Veillonella, etc.), while the microbial diversity of the control group had no significant change (p > 0.05). However, there was no significant difference between the two groups in the clinical parameters (p > 0.05).
Zeger therapy promotes the diversity of supragingival microbiome in adults with gingivitis and increases the abundance of some beneficial flora while decreasing some harmful without clinical parameters marked changing, which holds promise for improving of gingivitis and may be a valuable oral health care approach in the future.
The clinical trial was approved by the Medical Ethics Committee of West China Hospital of Stomatology, Sichuan University, batch No. WCHSIRB-D-2021-428. Before patient registration began, the prospective clinical trial was registered in www.
gov public repository in China under the registration number ChiCTR2200060555 on 04/06/2022.
本单盲随机对照试验旨在评估 Zeger 疗法对牙龈健康的微生物学和临床效果。
招募了 24 名患有牙龈炎的成年人，在基线（第 0 天）和治疗后 4 周（第 29 天）进行微生物学和临床监测。所有志愿者均接受了一次全口龈上洁治术作为基线的基本口腔保健，然后随机分为实验组（马奶酒，n=12）和对照组（无，n=12）。马奶酒每天使用一次，持续 4 周。
实验组饮用马奶酒后微生物多样性显著增加（p<0.05），主要归因于革兰阳性菌（p=0.038）和口腔健康相关微生物（罗氏菌、棒状杆菌、放线菌、糖细菌 TM7 等）增加，革兰阴性菌（p=0.009）和牙周病相关微生物（卟啉单胞菌、梭杆菌、韦荣球菌等）减少，而对照组微生物多样性无显著变化（p>0.05）。然而，两组临床参数无显著差异（p>0.05）。
Zeger 疗法可促进成年人牙龈炎龈上微生物组的多样性，增加一些有益菌群的丰度，同时减少一些有害菌群，而临床参数无明显变化，这为改善牙龈炎提供了希望，可能成为未来有价值的口腔保健方法。
本临床试验经四川大学华西口腔医院医学伦理委员会批准，批号 WCHSIRB-D-2021-428。在患者登记开始之前，本前瞻性临床试验在中国临床试验注册中心 www.chictr.org.cn 以 ChiCTR2200060555 号进行了注册。
Zotero 插件